Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities
21 Setembro 2023 - 9:30AM
Business Wire
Partnership Includes Education and Training to
Increase Clinician Confidence in the Use of CEM, an Emerging Breast
Imaging Modality
Hologic Inc. (Nasdaq: HOLX) and Bayer today announced an
international partnership to deliver contrast-enhanced mammography
(CEM) solutions to improve the detection of breast cancer for women
in multiple countries across the European, Canadian and Asia
Pacific regions.
CEM is a highly sensitive and relatively low-cost breast imaging
modality that combines digital mammography with the administration
of a contrast agent to support breast cancer diagnosis and guide
treatment decisions.1
The partnership brings together the companies’ leading
technologies (Hologic mammography gantries and Bayer CEM-approved
injection systems) to enable the administration of contrast media
during a mammography examination. With the new agreement, Bayer and
Hologic aim to optimally support radiologists and their teams’
needs by providing a comprehensive product package along with the
hands-on training needed to effectively implement CEM into their
facility’s workflow.
“Over the past several years, we’ve seen an increased interest
in contrast-enhanced mammography as an additional diagnostic
modality. Our partnership with Bayer will enable clinicians around
the world to offer CEM as part of the breast cancer diagnostic
workflow,” said Tanja Brycker, Vice President, Strategic
Development, Breast and Skeletal Health and GYN Solutions at
Hologic. “As one of the world leaders in mammography and women’s
health, we are committed to enabling healthier lives everywhere,
every day. By increasing access to additional breast imaging
technology to women across the globe, our international partnership
with Bayer is a compelling example of that commitment in
action.”
“Breast cancer is the world’s most prevalent cancer,2 impacting
millions of women and their loved ones around the globe,” said Gerd
Krueger, President of Radiology at Bayer. “Accurate and timely
detection is crucial to improve patient outcomes and save patients’
lives. We are excited to join forces with Hologic to deliver a
comprehensive solution to our customers and increase access to an
emerging breast imaging modality that can help improve diagnostic
accuracy as well as provide an alternative imaging option for many
women who need it.”
About Breast Cancer and Contrast-Enhanced Mammography
In 2020, there were 2.3 million women diagnosed with breast
cancer and 685,000 deaths globally, according to the World Health
Organization (WHO).2 Breast cancer treatment can be very effective,
especially when the disease is identified early. The value of CEM
as an adjunct to mammography is affirmed by an increasing number of
independent scientific publications. It can be performed as part of
an everyday clinical practice and used in various clinical
settings, such as inconclusive findings in previous imaging
procedures, or preoperative assessment of the extent of the
disease. It can also be a helpful tool when MRI is unavailable or
contraindicated.
About Hologic Inc.
Hologic Inc. is a global medical technology innovator focused on
improving the health and well-being of women, their families and
communities through early detection and treatment. Its advancements
include invention of the world’s first commercial 3D mammography
system to find breast cancer earlier; leadership in testing for
cervical cancer, sexually transmitted infections and respiratory
illnesses; and minimally invasive surgical technologies for uterine
fibroids, abnormal uterine bleeding and pediatric procedures. The
company also champions women through the Hologic Global Women’s
Health Index, which provides a science-backed data roadmap for
improving women’s well-being.
Hologic, 3D Mammography and The Science of Sure are trademarks
and/or registered trademarks of Hologic Inc., and/or its
subsidiaries in the United States and/or other countries.
About Radiology at Bayer
As a true life-science company with a heritage of over 100 years
in radiology, Bayer is committed to providing excellence — from
innovative products to high-quality services — to support efficient
and optimized patient care. Bayer offers a leading portfolio of
contrast media for computed tomography (CT), X-ray and magnetic
resonance imaging (MRI), along with devices for their precise
administration, informatics solutions and a medical imaging
platform delivering access to applications, including those enabled
by Artificial Intelligence (AI). Bayer’s radiology products
generated close to 2 billion euros in sales in 2022. Based on the
company’s ambition to outperform the radiology market’s average
annual growth rate of 5% by 2030, Bayer is highly committed to
research and development, which includes leveraging AI and driving
innovation in medical imaging. Each of these offerings provides
effective tools to support radiologists in their mission to deliver
treatment-critical answers and a clear direction — from diagnosis
to care.
About Bayer
Bayer is a global enterprise with core competencies in the
life-science fields of healthcare and nutrition. Its products and
services are designed to help people and the planet thrive by
supporting efforts to master the major challenges presented by a
growing and aging global population. Bayer is committed to driving
sustainable development and generating a positive impact with its
businesses. At the same time, the Group aims to increase its
earning power and create value through innovation and growth. The
Bayer brand stands for trust, reliability and quality throughout
the world. In fiscal 2022, the Group employed around 101,000 people
and had sales of 50.7 billion euros. R&D expenses before
special items amounted to 6.2 billion euros. For more information,
go to www.bayer.com.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
SOURCE: Hologic Inc.
_____________________ 1 Covington MF. Contrast-Enhanced
Mammography Implementation, Performance, and Use for Supplemental
Breast Cancer Screening. Radiol Clin North Am. 2021
Jan;59(1):113-128. doi: 10.1016/j.rcl.2020.08.006. Epub 2020 Oct
29. PMID: 33222993. 2 World Health Organization. Breast Cancer.
https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=As%20of%20the%20end%20of,increasing%20rates%20in%20later%20life.
Last accessed 6 September 2023.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230921375830/en/
Hologic Media Contact: Bridget Perry Director, Corporate
Communications +1 508.263.8654 bridget.perry@hologic.com
Hologic Investor Contact: Ryan Simon Vice President,
Investor Relations +1 858.410.8514 ryan.simon@hologic.com
Bayer Media Contact: Simone Leyendecker Communications
Business Partner Bayer Radiology +49 174.9508190
simone.leyendecker@bayer.com
Hologic (NASDAQ:HOLX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Hologic (NASDAQ:HOLX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024